|Validated Species:||Human, Mouse, Rat|
Data & Images
|Product Name||Anti-BRCA1 Picoband™ Antibody|
|Description||Rabbit IgG polyclonal antibody for Breast cancer type 1 susceptibility protein(BRCA1) detection. Tested with WB, IHC-P in Human;Mouse;Rat.|
|Cite This Product||Anti-BRCA1 Picoband™ Antibody (Boster Biological Technology, Pleasanton CA, USA, Catalog # PB9015)|
|Replacement Item||This antibody may replace the following items: sc-1021|sc-646|sc-28234|sc-7867|sc-56030|sc-641|sc-642|sc-1553|sc-135732|sc-6954|sc-135731|sc-646-G|sc-514640|sc-514797 from Santa Cruz Biotechnology.|
|Validated Species||Human, Mouse, Rat|
*Our Boster Guarantee covers the use of this product in the above tested applications.
**For positive and negative control design, consult "Tissue specificity" under Protein Target Info.
|Recommended Detection Systems||Boster recommends Enhanced Chemiluminescent Kit with anti-Rabbit IgG (EK1002) for Western blot, and HRP Conjugated anti-Rabbit IgG Super Vision Assay Kit (SV0002-1) for IHC(P).
*Blocking peptide can be purchased at $50. Contact us for more information
**Boster also offers various secondary antibodies for Immunoflourescecne and IHC. Take advantage of the buy 1 primary antibody get 1 secondary antibody for free promotion for the entire year 2018!
|Immunogen||E.coli-derived human BRCA1 recombinant protein (Position: E1661-Y1863). Human BRCA1 shares 65% and 66% amino acid (aa) sequences identity with mouse and rat BRCA1, respectively.|
|Cross Reactivity||No cross reactivity with other proteins|
|Contents||Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg NaN3.|
|Concentration||Add 0.2ml of distilled water will yield a concentration of 500ug/ml.|
|Storage||At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for a longer time.Avoid repeated freezing and thawing.|
|Purification||Immunogen affinity purified.|
Protein Target Info (Source: Uniprot.org)
You can check the tissue specificity below for information on selecting positive and negative control.
|Protein Name||Breast cancer type 1 susceptibility protein|
|Molecular Weight||207721 MW|
|Protein Function||E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8. Acts as a transcriptional activator (PubMed:20160719). .|
|Tissue Specificity||Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.|
|Sequence Similarities||Contains 2 BRCT domains.|
|Subcellular Localization||Nucleus . Chromosome . Cytoplasm . Localizes at sites of DNA damage at double-strand breaks (DSBs); recruitment to DNA damage sites is mediated by the BRCA1-A complex. Translocated to the cytoplasm during UV-induced apoptosis. .|
|Alternative Names||Breast cancer type 1 susceptibility protein;6.3.2.-;RING finger protein 53;BRCA1;RNF53;|
|Research Areas|||epigenetics and nuclear signaling|chromatin modifying enzymes|ubiquitylation| epigenetics and nuclear signaling|dna / rna|dna damage & repair|dna damage response|brca1| cell biology|proteolysis / ubiquitin|proteasome / ubiquitin|ubiquitin e3 enzymes|ring finger e3 ligase|transcription|cancer susceptibility|tumor suppressors| cancer|oncoproteins/suppressors||
Background for Breast cancer type 1 susceptibility protein
Dilution Ratios/Recommended Concentrations
At Boster we strive to provide the best Anti-BRCA1 Picoband™ Antibody by testing all applications on non-spiked tissues and cell lines to ensure that the affinity of the antibody is enough to react to the endogenouse level of the target protein. Read more about our QC panel here.
|Recommended dilution ratios are listed below:|
Immunohistochemistry(Paraffin-embedded Section), 0.5-1μg/ml, Human, Mouse, Rat, By Heat|
Western blot, 0.1-0.5μg/ml, Human
**Boster provides high sensitivity secondary antibody kits for Western blotting and IHC. For more info see Related Products below.
Anti-BRCA1 Picoband™ Antibody Images
Click the images to enlarge.
IHC(P): Mouse Testis Tissue
IHC(P): Rat Testis Tissue
IHC(P): Human Mammary Cancer Tissue
All lanes: Anti-BRCA1(PB9015) at 0.5ug/ml
Lane 1: HELA Whole Cell Lysate at 40ug
Lane 2: MCF-7 Whole Cell Lysate at 40ug
Lane 3: A549 Whole Cell Lysate at 40ug
Predicted bind size: 207KD
Observed bind size: 207KD
1. Post-translational modification:phosphorylation, methylation, glycosylation etc. These modifications prevent SDS molecules from binding to the target protein and thus make the band size appear larger than expected
2. Post-translational cleavage: this can cause smaller bands and or multiple bands
3. Alternative splicing: the same gene can have alternative splicing patterns generating different size proteins, all with reactivities to the antibody.
4. Amino Acid R chain charge: SDS binds to positive charges. The different size and charge of the Amino Acid side chains can affect the amount of SDS binding and thus affect the observed band size.
5. Multimers: Multimers are usually broken up in reducing conditions. However if the interactions between the multimers are strong, the band may appear higher.,